Evidencio's Medical Algorithms now available in the EPIC Showroom!
We are excited to announce that Evidencio's CE certified medical algorithms are now available in the connection hub in the EPIC Showroom, making integration into EPIC's electronic health record (EHR) system easier than ever. Healthcare providers using EPIC can seamlessly incorporate Evidencio's algorithms into their workflows, enhancing clinical decision-making with real-time data insights and predictive analytics.
By being part of EPIC's ecosystem, Evidencio empowers healthcare teams with intuitive tools that improve patient outcomes, streamline processes, and support precision medicine. Our solutions are designed to integrate effortlessly, allowing providers to enhance care delivery without additional technical hurdles.
For more information and to start integrating Evidencio into your EHR, visit the EPIC Showroom today.
Zorg & ICT presentation: Partnership between Roche Diagnostics and Evidencio for a marketplace with certified algorithms
Presentation: Tuesday 13 juni 2023 10:45 - 11:15 · 30 min Event Link
Prognostic and diagnostic medical algorithms are applied on an increasing scale within the Dutch healthcare landscape and far beyond. The Dutch software company Evidencio has a library of over 4,000 such algorithms of which about 600 are publicly available.
Since May 2021, the new European Medical Devices Regulation (MDR) applies. Algorithms used to support medical decision making are therefore classified as a Medical Device. This implies that they should be CE certified. However, for many developers/users of algorithms, this step is often a bridge too far.
Roche Diagnostics has entered into a strategic partnership with Evidencio. An innovative approach has led to a qualified system with which algorithms can be quickly provided with the required certification. This allows medical algorithms to be applied on a large scale, sustainable and cost-efficiently in clinical practice.
Strata Health and Evidencio announce partnership: Integrating Evidencio Algorithms in Strata Pathways
Calgary, AB: Strata Health announces partnership with Evidencio, incorporating its medical decision support algorithms within Strata PathWays assessment forms.
Evidencio’s platform includes over 2000 medical algorithms, trusted around the world to support medical decision-making, calculations and predictions. In the last few decades, the volume of scientific papers has increased exponentially. The resulting ‘big data’ pool houses an enormous potential but is still only marginally used in medical practice. The World Health Organization (WHO) has acknowledged this disconnect between science and medical practice as the “know-do gap”. Improvement of knowledge extraction, validation, and transferral is essential in order to utilize the untapped potential of medical databases.
Initial specialty areas that will incorporate Evidencio tools are cardiology and stroke, in the UK and Canadian markets respectively. Strata Health will continue to expand the use of the algorithms to support health care professionals using Strata PathWays, its class-leading patient flow solutions, across its global customer footprint.
“We’re excited for the large array of possibilities this integration with Evidencio presents. The initial use cases are immediately impactful, and we see great potential for existing and future clients.” Said President and CEO of Strata Health, Peter Smith. “Strata Health is always keen to incorporate better sources to extend our algorithms and Evidencio’s clinical decision support library is a perfect complement to our patient flow recommendation engine.”
Evidencio now offers a faster, cheaper and more convenient way to get your clinical algorithms to market as SaMD's
Three small icons, easily overlooked, yet indispensable when developing algorithms as Medical Devices.
There is a lot of buzz around algorithms and AI in healthcare. Yet, often the regulatory aspects of clinical application of developed tools is either overlooked or recognised too late. Evidencio now offers a faster, cheaper and more convenient way to get your clinical algorithms to market as SaMD's.
Evidencio COVID-19 protocollen
Sinds het begin van de uitbraak van het Coronavirus in Nederland zijn er verschillende instanties druk bezig geweest met het ontwikkelen van richtlijnen en protocollen voor de zorg van patiënten met COVID-19. De toestroom van informatie is in de afgelopen weken enorm geweest. Om de juiste informatie op de juiste tijd te kunnen krijgen hebben we met de functionaliteiten van Evidencio een aantal belangrijke richtlijnen vertaald naar dynamische interactieve protocollen.
Protocollen zijn ter beschikking gesteld voor zorgprofessionals op: https://covid19.evidencio.com/
De dynamische protocollen zijn ontwikkeld op basis van Nederlandse richtlijnen en zijn daarom ook alleen beschikbaar in het Nederlands.
De protocollen zijn ontwikkeld in samenwerking met Universitair Medisch Centrum Groningen (UMCG) en zijn gebaseerd op beschikbare documenten opgesteld door de SWAB, CIB, NVZA, NVMM, NVII en NVIC.
Royal college of obstetricians & gynaecologists provides guidance for maternal medicine services in the evolving coronavirus (COVID-19) pandemic
Due to recent and evolving coronavirus pandemic, health care professionals are forced to provide care in a different way than usual. The Royal college of obstetricians & gynaecologists have provided guidance for maternal medicine services. The guidance specifically provides recommendations regarding ideas for adaption of maternal services to safely reduce face-to-face contact while maintaining continuation of necessary care where it is safe to do so. Also, specific advice is provided for healthcare professionals caring for pregnant women with co-existing medical co-morbidities and suspected or confirmed COVID-19.
Several prediction models on the Evidencio platform are advised to use to support clinical decision making for maternal care. The relevant prediction models are linked below;
- PREP-S model: to predict risk of complications in early-onset pre-eclampsia.
- fullPIERS model: to predict maternal complications in women with any pre-eclampsia.
- EMPiRE model: to predict the risk for seizures in pregnant women not on sodium valproate.
- GDM model: to predict the risk for developing gestational diabetes mellitus.
The most recent version of the guideline can be downloaded at: https://www.rcog.org.uk/coronavirus-pregnancy
PARTNR project receives funding
The Dutch Cancer Society, the Dutch Research council, and the Life Sciences & Health Top Sector have awarded the project proposal for a Personalized cAnceR TreatmeNt and CaRe platform (PARTNR). The project is aimed at fatigue in women with breast cancer. Project will focus at data-driven approaches to implement personalized solutions to improve quality of life in women with cancer-related fatigue. Evidencio will collaborate in the research consortium which will be lead by the University of Twente. Other consortium partners are the Twente Hospital Group (ZGT), Roessingh rehabilitation centre, Netherlands Comprehensive Cancer Organisation (IKNL), UMC Groningen, Ivido, UMC Utrecht, Helen Downing Institute (HDI), and Roessingh Research and Development
More information on the topic can be found on the following website: https://www.nwo.nl/onderzoek-en-resultaten/programmas/ttw/partnership/17927.html
Evidencio present in trade mission to Boston with prime minister Mark Rutte and minister for medical care Bruno Bruins
We are very proud and thankful to have been part of the economic trade mission to Boston, organised by the Dutch Ministry of Health, Welfare, and Sport.
It has been a truly inspiring week with visits and talks from leaders in the field of Health and Life Sciences from a.o. Harvard, Beth Israel, Deaconess Medical Center, Tufts Medical center, Boston children's hospital, Wyss institute, JLabs, Amgen, and many more.
We were also given the opportunity to present our innovative platform for creating, validating, and integrating prediction models and decision support tools to the Dutch Prime Minister (Mark Rutte), the Minister for Medical Care (Bruno Bruins), and representatives from Boston's local companies, institutes and universities.
Thanks to the organisation for a very well organised trip.
ENVISION Conference in Austria
Last week we attended the European Collaborative On Early Diagnosis, Personalised Care And Prevention Of Breast Cancer (ENVISION) conference at the University for Health Sciences, Medical Informatics and Technology (UMIT) in Hall in Tirol in Austria.
We had the opportunity to present our online platform for the use, creation, validation, and integration of clinical prediction models and decision support tools.
Congratulations to the organisation for a very well organised conference with very interesting talks, discussions and activities.
New model to predict seizures in pregnant women
Researchers at the Queen Mary University of London have developed a new tool to predict seizures in pregnant women with epilepsy.
The model can be used to identify pregnant women at high risk of seizures and subsequently provide necessary treatment to reduce potentially harmful outcomes caused by seizures. Also see: New tool to predict epileptic seizures in pregnancy could save lives
The newly developed model, called the EMPiRE model, demonstrated good performance on both internal and external validation with a c-index of 0.76 on an external dataset.
The full model is publicly available for use on Evidencio:
https://www.evidencio.com/models/show/1799
The paper presenting the development and validation of the model is published at the open access journal PLOS medicine:
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002802
New update live
We have updated several features on the Evidencio platform and developed some new features to improve the use and usability of Evidencio. Some of our new features are:
- Language
- Model sharing
- Decision curve analysis
- Validation results
Newly published systematic review provides clear recommendations for future prediction models
Strijker et al. performed a systematic review of prediction models for survival after surgery for resectable pancreatic cancer. The study was published in the British Journal of SurgeryAfter screening 4403 studies, 21 models were identified of which 8 models can be used preoperatively and 13 models postoperatively. Only two models were found to have low risk of bias. Besides, most models were not validated externally. To improve future studies on prediction models for pancreatic cancer, Strijker et al. provided practical recommendations. One of their recommendations concerns the presentation of prediction models. Models should be presented as easily applicable to use (online) tools: Available for all clinicians and which can be used during clinical consultations. Evidencio facilitates the use of clinically useful prediction tools by allowing a large amount of prediction models to be accessed publicly. Also, anyone developing a prediction tool is able to create an online tool on the Evidencio platform. The systematic review by Strijker et al. can be accessed by clicking at this link: https://doi.org/10.1002/bjs.11111
Showcase: 14-day mortality risk prediction in nursing home residents with dementia and pneumonia treated with antibiotics
A new prediction model has been made available for public use on the Evidencio platform. The model predicts the mortality in nursing home residents with dementia and pneumonia treated with antibiotics. The paper was published in the Jounrals of Gerontology: Series A by Rauh et al. The model can be used to guide clinical decision making regarding treatment options for the nursing home residents. For instance, whether to prepare for the dying process and focus on comfort, or try to cure the pneumonia with antibiotic treatment. To predict the 14-day mortality, Rauh et al. have updated an earlier developed prediction model after validating the original prediction model. Patient data used to perform the analysis in the study were collected in the PneuMonitor study and consisted of 380 episodes in 341 nursing home residents who received antibiotic treatment for pneumonia. A total of 55 residents died within 14 days. Updating the prognostic model improved the discrimination of the model, assessed using the area under the curve from 0.76 (0.76 - 0.77) to 0.80 (0.80 - 0.81) The model can be accessed publicly on Evidencio by clicking this link: https://www.evidencio.com/models/show/1640 The original paper can be found by clicking this link: https://doi.org/10.1093/gerona/gly260
New risk score for distal pancreatectomy with celiac axis resection (DP-CAR)
The DP-CAR procedure is a treatment option for selected patients. To develop and validate a new risk score, Klompmaker et al. used patient data collected at centers located in Europe, the USA and Japan. The risk score predicts the risk of 90-day mortality using age, gender, ASA status, BMI, Multivisceral procedure, surgical approach, and hospital volume. The paper by Klompmaker et al. was published in the Annals of Surgical Oncology. The risk score was made publicly available on Evidencio just a few days before the paper was published online in the Annals of Surgical Oncology. Physicians with an interest in pancreatic cancer may also want to have a look at www.pancreascalculator.com where a list of clinical calculators is published that are being endorsed by the Dutch Pancreatic Cancer Group (DPCG). Click here to visit the DP-CAR score on Evidencio.
Poster presentation at the San Antonio Breast Cancer Symposium
In collaboration with the Netherlands Comprehensive Cancer Organisation (IKNL) and the University of Twente, a review on available prediction models for breast cancer care was performed. The results of the review were presented at the San Antonio Breast Cancer Symposium within one of the poster presentation rounds. We received a lot of interesting feedback and had some very nice discussions with the attendees of the symposium. We are currently working on drafting a manuscript which we will send in for peer-review publication.
Publication of a prostate cancer prediction model in British Journal of Cancer
Patients diagnosed with prostate cancer may receive radical treatment such as a prostatectomy. However, in patients with insignificant prostate cancer, active surveillance is the preferred treatment. Lorenzo Dutto and colleagues developed a risk score to predict the probability of having insignificant prostate cancer. The risk score incorporates PSA, prostate volume, age, clinical T stage, percent and number of positive biopsy cores. Dutto et al. suggest two different cut-off points to guide decision making in clinical practice. One cut-off point is aimed at reducing the risk of overtreatment. The other cut-off point is aimed at reducing the risk of missing a significant PCa. The clinical calculator on Evidencio was used within the peer-review process of publishing the study in the British Journal of Cancer. The calculator is publicly available over here.
Media attention for the INFLUENCE nomogram
The INFLUENCE nomogram predicts the 5-year risk of locoregional recurrence in patients who received curative treatment for breast cancer. The nomogram was developed in 2015 by Witteveen et al. at the University of Twente. November 2nd, Annemiek Witteveen succesfully defended her PhD thesis. In her thesis, Witteveen shows that the risk for locoregional recurrence is often quite low (i.e. on average around 3% risk). However, some patients have a 5-year risk lower than 1% where others have a 5-year risk higher than 10%. Besides, some patients prefer to see a physician every now and then to have a sense of security. Other patients are terrified to go back to the hospital for another follow-up meeting. Witteveen concluded that the follow-up schemes for patients treated for breast cancer can be more personalized according to a.o. the patients' risk and preferences. Her message was picked up by several Dutch news papers such as Trouw (article in Dutch). Click here to see the INFLUENCE nomogram on the Evidencio platform.
New publication of a breast cancer prediction model in British Journal of Cancer
Patients with a biopsy diagnosis of ductal carcinoma in situ (DCIS) may receive a different treatment than patients with invasive carcinoma. Yet, on several occasions, the DCIS diagnosis is underestimated whereas the patient actually has an invasive tumor. To guide clinical decision making regarding treatment options for potential underestimated DCIS, Meurs et al. developed a clinical prediction model. Meurs et al. used the Evidencio platform to create an online calculator which they published simultaneous with the publication of their paper in the prestigious British Journal of Cancer. Click on this link to see the model: A prediction model for underestimation of invasive breast cancer for patients with a biopsy diagnosis of ductal carcinoma in situ
Business in Biobanking event
Today we presented the Evidencio platform at the Business in Biobanking & Population Health Data Event. Our talk regarded how our platform enables a quick translation from scientific outcomes to clinical practice. We were able to connect with several interesting parties and had some great discussions on our talk. Thanks to the UMCG for the organization of this event. Interested in knowing more about how we gap the bridge between scientific outcomes and clinical practice? Contact us via info@evidencio.com or find more info at this web-page
Evidencio validation in European Urology Oncology Journal
Evidencio's validation tools have been used to externally validate models predicting lymph node involvement in prostate cancer patients. The results have been published in the European Urology Oncology Journal.
The validation showed that the Briganti Nomogram and the MSKCC Nomogram performed best at predicting lymph node involvement in Dutch prostate cancer patients.
Please read the full publication here.